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350 Randomized trials in interventional cardiology /  Early triage in acute myocardial infarction
BENESTENT-II trial: final results of visit II & ill: a 
7-month fol
E. Garcia, P.W. Serruys, K. Dawkins, C. Hanet, W, Rutsch, H, te Riele,
P. Crean, H. Hopp, P. Materne, G. Binhaghi. Thoraxcenter, Rotterdam, The 
Netherlands
The BENESTENT-II Trial is a randomized trial comparing the outcome after 
balloon angioplasty, with the effect of Heparin-coated Palmaz-Schatz stent (10, 
15 and 20 mm long) on the long-term effect of Major Adverse Cardiac Events 
(MACE: Death, Ml, Target Lesion Revascularisation [TLR]), in pts with stable 
or stabilized unstable angina pectoris with one or more de novo lesions. The 
secondary objectives are to assess the Cost-effectiveness and the restenosis 
rate. To that purpose a 1:1 sub-randomization to either clinical or angiographic 
foiiow-up was carried out. Concomitant medications consist of Aspirin (>100 
mg) and Ticlopidin (250 mg, 30 days) in the stent group. Between August 28th 
'95 and March 7th ’96, 827 patients were randomized to either treatment with 
stent (414) or balloon (413). Forty three percent of the patients had unstable 
angina, 51% stable and 6% silent ischemia. 6% underwent multiple lesion 
treatment. 54% of the lesions were B2 lesions (AHA/ACC). In the balloon group 
13.4% of the patients received a bail-out stent according to preset stringent 
criteria: procedural success was 97% in the stent group and 86% in the balloon 
group according to the actual allocation protocol.
Stent (208) Balloon (215)
MLD F/U (mm) 1.88 1.66 p = 0.0003
Restenosis rate 17% 31% p = 0.001
Stent (414) Balloon (413)
Death 1 (0.2%) 2 (0.5%)
Ml (Q/nonQ) 14 (3.4%) 14 <3.4%)
CABG 5 (1.2%) 7 (1.7%)
TLR 39 (9.4%) 57 (13.8%) RR: 0.68 (0.46-1.0)
Any Event 59 (14.3%) 80 (19.4%) RR: 0.74 (0.54-1.0)
It remains to be demonstrated whether elective stenting will be at long-term 
more cost-effective than balloon.
EARLY TRIAGE IN ACUTE MYOCARDIAL INFARCTION
Study of time intervals in myocardial ischaemic 
syndromes (STIMIS)
T.E.H. Hooghoudt \  E.J.P. Lamfers1, A. Uppefschoten1, F.W.A. Verheugt2.
1 Canisisius Withelmina Hospital Nijmegen, The Netherlands,2 University 
Hospital St. Radboud Nijmegen, The Netherlands
Early reperfusion in acute myocardial infarction improves long term prognosis. 
Treatment within the “Golden Hour" saves up to 7 lives per 100 treated patients. 
Prehospital thrombolysis has been practiced in Nijmegen since 1987. STIMIS 
was designed to assess the actual time intervals from onset of chest pain to 
treatment.
Methods: since Oct, 1995 all patients first seen by a general practitioner 
(GP), and presenting with typical chest pain, were eligible for STIMIS, whether 
or not a transtelephonic EKG (TT-EKG) had been transmitted by the ambulance 
staff and whether or not a myocardial infarction was diagnosed. Any EKG’s 
received were immediately interpreted. The time of all relevant events from 
onset of pain to treatment were registered on specially designed charts 
Results (n = 500): 292 TT-EKG’s were received; 73 (25%) fulfilled the criteria 
of acute myocardial infarction (AMI), 63 Patients received thrombolytic therapy 
at home, 36 were treated in hospital. Within one hour 24% (n = 15) of the home 
treated patients and none of the hospital treated patients received thrombolysis 
(p = 0.0034). Within two hours these data are 70% (n = 44) and 17% (n = 6) 
respectively (p = 0.0002),
Prehospital time intervals In-hospital time Intervals
Chest pain -  GP arrival 1:15 Chest pain -  Hospital door 2:17
GP arrival -  Ambulance arrival 0:20 Hospital door -  EKG 0:08
Ambulance arrival -  TT-EKG 0:10 EKG -  Doctor at bedside 0:08
TT-EKG -  Diagnosis 0:03 Doctor -  Diagnosis 0:05
Dlagnosis-Thrombolysls 0:05 Diagnosls-Thrombolysis 0:15
Diagnosis -  Departure 0:10
Departure -  Hospital door 0:12 (All median values in hrs-.min)
Time to treatmenl 1:30 Time to treatment 2:42
Conclusions: In the current setting in Nijmegen, with 12 ambulances 
equipped with TT-EKG transmitters and EKG confirmation by cardiology resi­
dents, a time gain of 72 minutes is obtained when thrombolysis is administered 
at home. Moreover 70% of home treated patients receive thrombolysis within
2 hours, in comparison with only 17% of the in-hospital treated patients.
Factors of importance for time to start of thrombolysis 
in acute myocardial infarction
U. Stenestrand, L. Wallentin1 on behalf of the National Registry of Coronary 
Care in Sweden. Department of Cardiology University Hospital, Linköping, 
Sweden, 1 Department of Cardiology University Hospital Uppsala, Sweden
Time to start of thrombolysis is of utmost importance for outcome in acute 
myocardial infarction (Ml). We investigated clinical factors influencing time to 
treatment in routine care.
Method: The Swedish national registry for coronary care includes every 
patient admitted to participating© CCUs. Clinical background, treatment, com­
plications and key time points were recorded in 1604 patients with acute Ml 
treated with thrombolysis within 12 hours after start of pain in 19 hospitals in 
1995.
Results:
Time intervals {n = 1604) 25% Median 75%
Beginning of pain -  start of treatment 2,15 hours 3.30 hours 5.40 hours
Start of pain -  arrival hospital 1.15 hours 2.10 hours 3.75 hours
Arrival hospital -  start of treatment 0,65 hours 0,92 hours 1.50 hours
Significance of univariate (uni) and multivariate (multi) regression analysis:
Time Intervals Pain-start Pain-arrival Arrival-start
Regression analysis Uni Multi Uni Multi Uni Multi
Increasing age (+) <0.001 0.001 0.001 0.001 0.035 ns
Female gender (+) 0.003 ns 0.013 ns 0.005 ns
Diabetes mellitus (+) <0.001 0.01 0,02 ns 0.003 ns
Q-wave or LBBB {+) <0.003 0.007 0.001 ns ns ns
ST-elevation ( - ) <0.001 0.001 ns ns 0.001 o.oot
Max CKMB level (-) ns ns ns ns 0.001 0.001
Hospitals significantly (-f) 1 1 1 1 5 5
Hospitals significantly ( - ) 3 0 2 0 3 2
(+) increased delay ( - )  reduced delay. Nonsignificant p > 0.01.
Conclusions: Delay to thrombolysis is above 3.3 hours in half of patients and 
is prolonged in older age, diabetes mellitus, Q-waves or LBBB and shortened 
at ST-elevatlon. Of the delay 2/3 occurs before arrival to hospital which mainly 
is influenced by age. Hospital organisation and disease related factors have the 
largest impact on delay in hospital. Reduced times to treatment will necessitate 
measures both before and after arrival to hospital.
1963 Indication for thrombolysis in acute myocardial
infarction: determinants for decision making in daily 
clinical practice
U. Burczyk, R. Schiele, S. Schuster, A. Koch1, R. Uebls2, D. Behrenbeck3,
J. Senges on behalf of the ALKK Study Group. Herzzentrum, Ludwigshafen,
1ZMBT Heidelberg, 2 Klinikum, Aschaffenburg, 3 Städtisches Krankenhaus, 
Solingen, Germany
Recent trials demonstrated that thrombolytic therapy Is beneficial in a much 
wider range of patients with acute myocardial infarction (AMI), e.g. patients 
with late presentation (6-12 h) and the elderly. However, it remains unclear 
how these guidelines are implemented in clinical practice.
Methods: 'The 60-Minutes Myocardial Infarction Project" is a prospective 
multicenter registry in Germany, which enrolled all patients with proven Q-wave 
Ml in 136 hospitals (27 months, n = 14,980). 50.5% of patients received 
thrombolysis. Indication for thrombolytic therapy was analyzed with respect 
to 15 relevant factors by a multivariate logistic regression expressed as odds 
ratios (OR) and 95%-confldence intervals (Cl).
Results:
Rate (%) OR 95%-Cl
Diagnostic ECG or LBBB on admission 71.6 4.79 3.67-6.25
Systolic blood pressure <90 mm Hg 11.1 1.30 1.11-1.52
Previous infarction 19.3 0.86 0.77-0.96
Female gender 31.7 0.80 0.70-0.90
Relative contraindications 22.5 0.28 0.23-0.35
Age >70 y 35.7 0.27 0.24-0.31
Prehospital delay 6-12 h 12.5 0.23 0.17-0.31
An OR > 1 refers to a higher chance to be treated with thrombolysis.
Conclusions: A diagnostic ECG on admission is the most important deter­
minant in the decision making to administer thrombolytic agents in AMI. Pts. 
with hemodynamic impairment are more likely to be treated with thrombolysis. 
Female gender Is an independent risk factor not to receive thrombolytic ther­
apy. Physicians tend to be restrictive, if relative contraindications are present. 
Despite documented benefit, fibrinolytic therapy is withheld in pts. with previous 
infarction, higher age and late presentation.
